• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

    19.57 +0.77 (+4.10%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 749,309
    Open 18.81
    Bid (Size) 18.91 (100)
    Ask (Size) 23.13 (100)
    Prev. Close 18.80
    Today's Range 18.56 - 19.89
    52wk Range 3.510 - 25.77
    Shares Outstanding 49,383,711
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise ↗
    This biotech focused on precision medicines for cancer and immune disorders disclosed a notable insider sale after a strong year for shares. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +27.8%
    +27.8%
    1 Month
    +14.5%
    +14.5%
    3 Month
    -6.3%
    -6.3%
    6 Month
    +62.1%
    +62.1%
    1 Year
    +293.8%
    +293.8%

    More News

    Read More
    News headline image
    Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount ↗
    Via Stocktwits
    News headline image
    Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher ↗
    Via MarketBeat
    Nasdaq, S&P 500 Futures Pause Ahead Of Jobs Report, Trump Tariff Ruling: Why OPEN, INTC, NVDA, TLRY, CRMD, GLUE Are On Traders' Radar Today ↗
    Via Stocktwits
    Topics Government Stocks
    News headline image
    Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets
    Via MarketMinute
    Topics Artificial Intelligence Economy Initial Public Offering
    News headline image
    Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
    Via Chartmill
    The market is filled with gapping stocks in Wednesday's session. ↗
    Via Chartmill
    News headline image
    Why Did GLUE Stock Surge Over 50% In Premarket Today? ↗
    Via Stocktwits
    Wednesday's pre-market session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Tuesday's after hours session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Q3 2025 Earnings Beat Estimates, Stock Rises ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Monte Rosa Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Monte Rosa Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Monte Rosa Therapeutics, Inc. - Common Stock trade on?
    Monte Rosa Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock?
    The ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock is GLUE on the Nasdaq Stock Market
    What is the current price of Monte Rosa Therapeutics, Inc. - Common Stock?
    The current price of Monte Rosa Therapeutics, Inc. - Common Stock is 19.57
    When was Monte Rosa Therapeutics, Inc. - Common Stock last traded?
    The last trade of Monte Rosa Therapeutics, Inc. - Common Stock was at 05/04/26 04:00 PM ET
    What is the market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock?
    The market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock is 966.44M
    How many shares of Monte Rosa Therapeutics, Inc. - Common Stock are outstanding?
    Monte Rosa Therapeutics, Inc. - Common Stock has 966M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.